TheEdgeResearch
Home / Stocks / TIHE

Taihe Group, Inc. (TIHE)

OTC Healthcare Medical - Diagnostics & Research
$1.00 ▲ +0.00%
Market Cap
$71.9M
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Beta
1.23
52-Wk Range
1-3.3
CEO
Yan Ping Sheng
Country
US
Currency
USD

Taihe Group, Inc. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Scottsdale, AZ, US. The stock last traded at $1.00, up 0.00% on the session, giving a market capitalisation of $71.9M. On trailing twelve-month figures it carries a trailing P/E of -1428.57, a net margin of 0.0%. Its beta of 1.23 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-1428.57
Price / Sales
0.00
Price / Book
-1427.06
EV / EBITDA
-1635.15
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
-0.95
Current ratio
0.00
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
3
IPO date
1998-07-10
Headquarters
Scottsdale, AZ, US
About Taihe Group, Inc.

Currently, Taihe Group, Inc. is not engaged in substantial operational activities. Historically, the company functioned as a commercial laboratory, providing specialized predictive tests for chemosensitivity and immunotherapy on biopsy samples, alongside a variety of other laboratory services and products within the field of oncology. Established in 1994, the Scottsdale, Arizona-based entity was formerly known as NuOncology Labs, Inc. until it adopted the name Taihe Group, Inc. in April 2022.

Comparable companies

Taihe Group, Inc. is most often compared with the following Healthcare names:

BIOGFEEOIFEOFBYETXPFGDNSFKDEVFKIARFNVACFRTGNSYMQY
More research on TIHE
TIHE technical analysis TIHE TheEdge Score Compare against peers
Open full interactive analysis & DCF →